Efficacy and safety assessment of T4032 (unpreserved bimatoprost 0.01%)
Laufzeit: 01.01.2019 - 31.12.2020
imported
Kurzfassung
International, multicentre, randomised, 2 parallel groups, investigatormasked
Laufzeit: 01.01.2019 - 31.12.2020
International, multicentre, randomised, 2 parallel groups, investigatormasked